Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers
    2.
    发明申请
    Stable Pharmaceutical Solution Formulations for Pressurized Metered Dose Inhalers 审中-公开
    用于加压计量吸入器的稳定的药物溶液制剂

    公开(公告)号:US20070025920A1

    公开(公告)日:2007-02-01

    申请号:US11467515

    申请日:2006-08-25

    IPC分类号: A61L9/04 A61K31/4704

    摘要: Aerosol solution formulations for use in an aerosol inhaler include 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methyl ethyl]amino]ethyl]-2(1H)-quinolinone or a salt thereof, preferably the hydrochloride thereof, as an active ingredient, a propellant containing a hydrofluoroalkane, and a cosolvent, stabilized by addition of a specific small amount of a high concentrated phosphoric acid and optionally by the use of a suitable can having part or all of its internal metallic surfaces lined with an inert organic coating.

    摘要翻译: 用于气溶胶吸入器的气溶胶溶液制剂包括8-羟基-5 - [(1R)-1-羟基-2 - [[(1R)-2-(4-甲氧基苯基)-1-甲基乙基]氨基]乙基] -2(1H) - 喹啉酮或其盐,优选其盐酸盐作为活性成分,含有氢氟烷烃和助溶剂的推进剂,通过加入特定量的高浓度磷酸和任选地通过 使用合适的罐,其具有内部具有惰性有机涂层的部分或全部内部金属表面。

    Pharmaceutical aerosol composition containing HFA 227 and HFA 134a
    5.
    发明授权
    Pharmaceutical aerosol composition containing HFA 227 and HFA 134a 失效
    含有HFA 227和HFA 134a的药物气溶胶组合物

    公开(公告)号:US06713047B1

    公开(公告)日:2004-03-30

    申请号:US09831886

    申请日:2001-07-18

    IPC分类号: A61K912

    CPC分类号: A61K9/008

    摘要: In a solution composition for use in an aerosol inhaler which comprises an active material, a propellant containing a hydrofluoroalkane, a cosolvent and optionally a low volatility compound the use of a mixture of HFA 134a and HFA 227 allows to modulate the mass median aerodynamic diameter (MMAD) of the aerosol particles on actuation of the inhaler to target specific regions of the respiratory tract. Moreover the fine particle dose (FPD) of the active ingredient in the composition increases by reducing the metering chamber volume.

    摘要翻译: 在用于气溶胶吸入器的溶液组合物中,其包含活性物质,含有氢氟烷烃,助溶剂和任选的低挥发性化合物的推进剂,使用HFA134a和HFA227的混合物允许调节质量中值空气动力学直径( MMAD)气雾剂颗粒在致动吸入器以靶向呼吸道的特定区域时。 此外,组合物中活性成分的细颗粒剂量(FPD)通过减少计量室体积而增加。